Antisense compositions and methods for modulating type I interleukin-1 receptor expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsLoren Miraglia, C. Frank Bennett, Nicholas Dean, Thomas Geiger
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of type I IL-1 receptor mRNA expression. In accordance with preferred embodiments, oligomers are provided which are specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor. Methods of modulating type I IL-1 receptor expression and of treating animals suffering from diseases amenable to therapeutic intervention by modulating the expression of type I interleukin-1 receptor with an oligomer specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor are disclosed.
Claims29
An oligomer comprising nucleosides, connected via covalent linkages, consisting of SEQ ID NO:
- 27, 28, 30-34 or 40 wherein at least one of said nucleosides bears a 2'-substituent.
An oligomer comprising nucleosides, connected via covalent linkages, consisting of SEQ ID NO:
- 27, 28, 30-34 or 40, said oligomer comprising a first subsequence and a second subsequence, wherein:
- said first subsequence has at least one nucleoside bearing a 2'-substituent;
- and
- said second subsequence comprises 2'-deoxy-erythro-pentofuranosyl-.beta.-nucleosides.
A method of modulating the expression of type I interleukin-1 receptor in a cell or tissue in vitro comprising contacting the cell or tissue with an oligomer specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor, said oligomer comprising nucleosides, connected via covalent linkages, consisting of SEQ ID NO:
- 27, 28, 30-34 or 40 wherein at least one of said nucleosides bears a 2'-substituent.
A method of modulating the expression of type I interleukin-1 receptor in a cell or tissue in vitro comprising contacting the cell or tissue with an oligomer specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor, said oligomer comprising nucleosides, connected via covalent linkages, consisting of SEQ ID NO:
- 27, 28, 30-34 or 40, said oligomer comprising a first subsequence and a second subsequence, wherein:
- said first subsequence has at least one nucleoside bearing a 2'-substituent;
- and
- said second subsequence has nucleosides comprising 2'-deoxy-erythro-pentofuranosyl-.beta.-nucleosides.
Dependencies are inferred from the claim text.